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Introduction 
In the United States, thyroid cancer (TC) has the highest 
rate of growth among diagnosed tumors (1). TC accounts 
for 6% of women cancers and less than 3% of men cancers.
Even if most of TCs are sporadic (2), the nuclear 
disasters and the resulting radiation exposure (for instance, 
Chernobyl, 1986), represent significant risk factors for TC 
development (3-5). 
Papillary TCs (PTCs) and follicular TCs (FTCs) arise 
from follicular cells and represent the majority of TCs 
(90%), while medullary TCs arise from para-follicular 
C-cells, and are by far less common (5%). Thyroid 
malignancies span from the well-differentiated to the poorly 
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differentiated or undifferentiated (anaplastic) cancers (6).
Standard treatment for TC usually includes primary 
surgery (near-total or total thyroidectomy and lymph nodes 
dissection if necessary), ablation of the thyroid remnant 
with radioactive iodine (RAI) (based on the tumor stage) 
and thyroid-stimulating hormone (TSH) suppressive 
therapy (7). 
Follow-up consists of neck ultrasonography (US), 
performed basally and after TSH-stimulated thyroglobulin 
assay (7-10).
Though TC has generally a good prognosis, 10% to 
15% of patients with TC have recurrent disease, and about 
5% will develop metastatic disease not responsive to RAI, 
and eventually will die from this disease (11-14). 
For these reasons an early diagnosis of TC is needed 
in patients with thyroid nodules. US along with fine-
needle aspiration (FNA) cytology (FNAC) are determinant 
to differentiate benign thyroid nodules from malignant 
nodules (7).
In order to improve FNAC accuracy in detecting 
malignancies,  testing for oncogene mutations has 
been proposed (15,16), suggesting that it improves the 
performance of FNA diagnosis when it is performed in 
indeterminate cytology, supporting the clinician’s decision 
making process in several settings of uncertain diagnosis. 
Testing for multiple mutations [BRAF, RAS, RET/PTC, 
PAX8/peroxisome proliferator-activated receptor (PPAR)γ] 
improves the performance and increases the specificity, but 
it does not increase the sensitivity as well (15). 
For these reasons, molecular diagnostic is recommended 
in the 2015 revised American Thyroid Association 
management guidelines in the cases of patients with thyroid 
nodules and differentiated TC (DTC) with indeterminate 
cytology (17).
This study aims to review the potential advantages of 
assessing the gene-related cancer status on samples obtained 
with FNA, and their prognostic relevance.
Molecular pathways implicated in TC
Rearranged during transfection (RET)
RET is a proto-oncogene (located on 10q11.2) encoding a 
transmembrane protein harboring intracellularly a tyrosine 
kinase (TK). Activating RET mutations and rearrangements 
have been reported in human cancers (18). RET/PTC 
rearrangements have been identified in about 40% of adult 
sporadic PTC (19). The most common are RET/PTC1, 
and RET/PTC3, often reported in microcarcinomas and 
benign thyroid lesions, leading to hypothesize that RET/
PTC can be determinant for tumor initiation, but not 
progression (20-24). 
RAF kinase
The BRAF kinase belongs to RAF family proteins; a BRAF 
mutation [substitution from valine to glutamate at residue 
600 (V600E)] is present in approximately 45% of PTC, 
associated with tumor aggressiveness (24). 
Vascular endothelial growth factor (VEGF) 
TC aggressiveness and increased angiogenesis are 
correlated (25), and the expression of VEGF/VEGF 
receptor (VEGFR), platelet-derived growth-factor (PDGF)/
PDGFR, fibroblast growth factor (FGF)/FGFR, epidermal 
growth factor (EGF)/EGFR, and hepatocyte growth factor 
(HGF)/c-Met (that stimulate or inhibit angiogenesis) is 
associated with clinical features of TC (26). VEGF and its 
principal receptor VEGFR-2 are overexpressed in DTC (27) 
and are implicated in tumor progression and aggressive 
behavior. Drugs that target VEGF pathway are indeed a 
therapeutic approach in TC (28).
Histone acetylation
On histones the acetylation of NH2-terminal lysine 
controls cellular differentiation and biological behavior of 
neoplastic cells. 
A more open chromatin configuration leads to an increase 
in gene transcription rate while a closed chromosomal 
configuration is linked to transcriptional repression (29). 
The dysregulation of histone acetyltransferase or histone 
deacetylase (HDAC) activity is present in some neoplastic 
cells (30-33). 
The HDAC inhibitors depsipeptide, vorinostat, 
belinostat, valproic acid, and panobinostat have an 
antineoplastic effect on TC cells (34).
Epidermal growth factor receptor (EGFR)
The EGFR cell-surface protein (ErbB-1; HER1 in humans) 
is part of the ErbB family of receptors (35), a subfamily of 
four closely related receptor TKs: EGFR (ErbB-1), HER2/
c-neu (ErbB-2), HER3 (ErbB-3) and HER4 (ErbB-4).
Mutations can cause EGFR upregulation or over 
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activity, that have been correlated with various cancers, as 
lung cancer, anal cancer (36) and glioblastoma multiform 
(in which EGFRvIII results to be the most frequent 
mutation) (37). 
Mutations, amplifications or misregulations of EGFR or 
of other family members are present in approximately 30% 
of all epithelial tumors, and EGFR is determinant in tumor 
progression and invasion in TC and is overexpressed in 
anaplastic TC (ATC) (38-40). 
RAS
The RAS gene family members N-RAS, H-RAS, and K-RAS 
encode for intracellular G-proteins participating in the 
activation of intracellular signal pathways. Approximately 
40–50% of FTCs and 10% of PTCs show RAS mutations 
(associated with a more aggressive TC behavior) (41).
TERT
The major part of normal cells does not have telomerase 
activity, while the upregulation of TERT transcription/
activity is shown in 80–90% of malignant tumors. 
In different kinds of cancer, the presence of TERT 
promoter mutations, TERT mRNA expression and 
clinicopathological features are associated, even if the link 
between the occurrence of TERT promoter mutations and 
tumor aggressiveness is not known. Even the association 
between TERT promoter mutations and metastisation/
survival has been reported in different cancers. In follicular 
cell-derived TC, such mutations are associated with worse 
prognostic features (age of patients, tumor size and stage) 
and distant metastases, less response to treatment and poor 
survival (42-44).
PAX8/peroxisome proliferator-activated receptor γ (PPARγ) 
rearrangements
PAX8/PPARγ rearrangements are detected in typical FTC 
(30–40%) and in Hürthle cell tumors (5%) (45), and their 
presence is linked to a good prognosis.
Tumors presenting PAX8/PPARγ rearrangements do 
not have any RAS mutation, leading to hypothesize the 
coexistence of two separate mechanisms (PAX8/PPARγ 
translocation or RAS oncogenic activation) that contribute 
to the development of FTC (45). 
PAX8/PPARγ rearrangements are detected in follicular 
adenomas (FAs; 2–10%), as in the follicular variant of PTC 
(FVPTC) (46,47). Approximately 0–1% of PTCs have 
PAX8/PPARγ translocations (46).
Molecular diagnosis of thyroid nodules 
Thyroid nodules are very common, since 5% of women 
and 1% of men have palpable nodules in iodine-sufficient 
countries. However, 19–67% of randomly selected individuals 
have thyroid nodules detectable by US (7). TC occurs in 
5–15% of thyroid nodules, depending on age, sex, radiation 
exposure history, family history, and other factors (48). 
Early diagnosis of malignant thyroid lesions allows to 
achieve a curative total thyroidectomy. For this reason, it is 
crucial to distinguish them among thyroid nodules, which 
are very often benign (49).
At present the combination of FNA with cytological 
evaluation is the common preoperative diagnostic method 
in TC, even though a number between 10% and 40% 
of cytological specimens still result indeterminate for 
malignancy (50). 
Since 2008, the indeterminate cytology is classified 
in the following three subclasses: “follicular lesion of 
undetermined significance”, “follicular or oncocytic 
(Hürthle cell) neoplasm”, and “suspicious for malignancy”. 
These subclasses express the malignancy chance of 5–10%, 
15–30%, and 50–75%, respectively (51).
Molecular testing of FNA biopsies (FNABs), overall 
for BRAF, and for other markers as RET/PTC, PAX8/
PPARγ, BRAF, and RAS, is possible and can significantly 
ameliorate the accuracy of the preoperative FNA diagnosis 
by cytology (52-62). In patient with indeterminate cytology, 
the investigation for genetic markers (PAX8/PPARγ, BRAF, 
RAS, and RET/PTC) and protein markers (galectin-3) 
has demonstrated to improve the accuracy of pre-surgery 
diagnosis (56-58,63-65). Furthermore, the use of molecular 
markers (i.e., RET/PTC, BRAF, RAS, PAX8/PPARγ or 
galectin-3) is now formally advised for indeterminate 
cytological samples in the “2009 Revised American Thyroid 
Association (ATA) Management Guidelines for Patients 
with Thyroid Nodules and Differentiated Thyroid Cancer” 
(Recommendation rating: C) (7). 
BRAF 
A number of studies (56-60,64,66-72) have reported 
that molecular testing for BRAF V600E in thyroid FNA 
samples significantly ameliorates the accuracy of cytological 
diagnosis of thyroid nodules. A recent meta-analysis of 
Ferrari et al. Molecular diagnostic in thyroid nodules
© Gland Surgery. All rights reserved.   Gland Surg 2018;7(Suppl 1):S19-S29gs.amegroups.com
S22
18 studies reporting the results of BRAF testing in 2,766 
thyroid FNA samples demonstrated that among 581 BRAF-
positive cases, 580 were PTCs (73). Therefore just one 
BRAF-positive specimen collected from a thyroid nodule 
of resected gland, disclosed benign nature (74). Even if this 
case is recognized as a false-negative, the rate of malignancy 
in BRAF-positive nodules tested by FNA was 99.8%. 
Several studies have reported that 15–39% of BRAF-
positive FNA samples were indeterminate or non-diagnostic 
by cytology, demonstrating that testing for BRAF is helpful 
in establishing a definitive diagnosis of cancer in nodules 
with indeterminate cytology (58,60,66,75-77).
Many authors have investigated the role of BRAF 
mutation in PTC; the data indicate that BRAF V600E 
mutation is an important prognostic molecular marker that 
improves FNAB diagnostic accuracy, but is complementary 
to cytology and US (61).
In fact, BRAF V600E mutation was significantly associated 
with malignant US features (solid composition, marked 
hypoechogenicity, irregular margin, taller-than-wide shape 
and the presence of microcalcification) (78), and also with 
poor prognostic factors and increased tumor size (79). 
As regards FTC, detection of BRAF mutation had 
limited value, but in case of suspicious for malignancy 
FNABs can be helpful and results are associated with risk of 
extra-thyroidal extension and metastases after surgery (80). 
A perspective study published in 2012 assessed the 
usefulness of US-guided FNAB in the diagnosis of nodules 
with/without clinical/US features suggestive for malignancy 
and to evaluate the contribution of BRAF V600E mutation 
analysis in the detection of DTC. Thyroid cytoaspirates 
from 2,421 nodules at least 4 mm in diameter were done 
in 1,856 patients submitted to cytological evaluation and 
bimolecular analysis.
Cytology had high positive predictive value and 
specificity for the diagnosis of malignant lesions. BRAF 
V600E mutation was reported in 115 samples, and 80 of 
them had also a diagnosis of PTC. The evaluation of the 
presence of a BRAF mutation significantly improved the 
diagnostic value of cytology, increasing FNAB diagnostic 
sensitivity for malignant nodules of about 28% (81). 
Recently Howell et al. published a single-center, 
retrospective review (82) of all patients who had initial 
thyroidectomy for histologic PTC during 2010. The 
possible correlation between central compartment lymph 
node metastasis (CLNM) and available preoperative clinical 
parameters (as age, gender, tumor size, and BRAF mutation 
status) was evaluated. Considering the common clinical 
preoperatively available parameters, the BRAF V600E 
mutation was the only independent predictor of CLNM 
in PTC and could be utilized to guide the extent of initial 
surgery (82).
In a recent paper, Kabaker et al. have confirmed that 
BRAF-positivity is correlated with the most known 
suspicious US findings, such as hypoechogenicity, ill-
defined margins, calcifications, absent halo and taller-
than-wide shape (83). Moreover, the positive predictive 
value raised to 82% when three or more US such features 
were present, while the negative predictive value (BRAF-
negativity plus no US features) was 88% (83). 
As up-to-date meta-analysis showed, BRAF mutation 
offers very high grade of specificity (97.9%) and positive 
predictive value (99.9%) with only 7 false positives described 
by 3 studies (74,84,85) of a total of 26, which included the 
evaluation of 2,800 malignant and benign thyroid neoplasms. 
Various techniques have been adopted to detect this marker 
without affecting the results, which remained constant 
(61-66,73-86) [from Rodrigues et al. (87)].
RET/PTC
Testing for RET/PTC rearrangements can be helpful 
for the diagnosis of TC. In thyroid FNA samples, RET/
PTC detection can ameliorate the preoperative diagnosis 
of thyroid nodules, especially in samples resulting 
indeterminate by cytology or without a sufficient amount 
of cells for the cytological evaluation (54,60,66). In 
2 prospective studies (58,64), all 16 thyroid nodules positive 
for RET/PTC were found to be PTCs after surgery, and 
many of those nodules were indeterminate by cytology. In 
another recent study (56) 5/6 nodules positive for RET/
PTC in the FNA material were malignant, and 1 nodule 
was found to be benign after surgery. 
Recently, Ferraz et al. have shown the feasibility of testing 
for RET/PTC rearrangements from routine FNA (88).
The conclusions of a more recent meta-analysis (87) are 
that the RET/PTC has shown average values of specificity 
(18%) and positive predictive value (87%).
RAS
The importance of RAS mutation detection lies in the 
fact that it represents a marker of FVPTC, which is most 
difficult to diagnose, in particular by FNAC. RAS mutations 
are the second most common mutation type detected in 
consecutive FNA samples from thyroid nodules (89).
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A retrospective study on 341 patients with TC showed 
an association between malignancy and N-RAS mutation, 
as well as with tissue inhibitor of metalloproteinases-1 and 
FNAC result (90). In several prospective studies (58,64), 
RAS mutation had a 74% to 88% positive predictive value 
for malignancy. Importantly, RAS mutations were identified 
in tumors that were difficult to diagnose with only cytology, 
which is FVPTC and FTC. Some RAS-positive nodules 
were diagnosed as benign FAs, formally contributing to a 
false-positive rate. It is likely that RAS-positive FAs serve 
as precursor lesions for RAS-positive FTC and possibly 
FVPTC, and RAS mutation apparently predisposes the 
well-differentiated cancer to dedifferentiation and more 
aggressive behavior (91-96).
In a more recent meta-analysis (87), RAS mutations have 
displayed average values of specificity (23%) and positive 
predictive value (82%).
PAX8/PPARγ
Detection of PAX8/PPARγ rearrangement in a follicular 
lesion is not fully diagnostic for malignancy by itself, but 
it should encourage the pathologist to perform a complete 
search for vascular or capsular invasion. Although it may 
not be seen at first, the invasion is found in many PAX8/
PPARγ-positive follicular tumors after examination of the 
entire capsule in multiple histologic levels (97,98).
PAX8/PPARγ rearrangement can be detected in thyroid 
FNA samples, and this correlates with the presence of 
malignancy, even if only few positive cases were reported so 
far in prospective studies (58,59).
Recently, Ferraz et al. have shown also the feasibility 
of testing for PAX8/PPARγ rearrangements from routine 
FNA (88).
In a more recent meta-analysis (87), PAX8/PPARγ 
mutations have shown average values of specificity (20%) 
and positive predictive value (100%). 
Multiple testing
One prospective study, which compared cytology alone 
or combined with molecular testing for RET/PTC, 
BRAF, PAX8/PPARγ, and RAS mutations, demonstrated 
to increase the FNA sensitivity for malignancy of thyroid 
nodules from 44% to 80%, respectively (58). 
 After surgery, 31/32 (97%) mutation-positive nodules 
were diagnosed as malignant, and 1/32 (3%) as a RAS-
positive FA, suggesting the detection of each mutation can 
be considered a good predictor of malignancy (58). After 
surgery, considering the indeterminate FNA samples, 
molecular testing permitted to identify 15/21 (71%) 
malignant nodules, indicating that molecular testing can 
ameliorate the diagnosis of indeterminate FNAs (58). 
Another paper showed that the sensitivity of malignant 
diagnosis in FNA rised from 60% to 90%, combining 
cytology with molecular testing for TRK, PPARγ, BRAF, 
RAS, and RET mutations to cytology alone (64). Mutations 
were associated with cancers in 61/67 mutation-positive 
patients (91%) and with benign FA in 6/67 mutation-
positive cases (9%), indicating as the previous study that 
the presence of a mutation could be a good predictor of 
malignancy. The usefulness of these markers in the pre-
surgery setting is still under investigation.
Recently in a prospective study of Borrelli et al. (99) 
different consecutive FNA samples were assessed by 
independent cytological and molecular means. BRAF 
was mutated (by Sanger method) in the suspicious and 
malignant cases, but not in TIR1, TIR2, and TIR3 cases, 
suggesting that BRAF mutational analysis does not improve 
the cytological diagnosis.
A BRAF mutation was reported in only 3 patients (4.4%), 
analyzing the indeterminate nodules (cytological TIR3 
cases) by the Easy BRAF kit, that is a very sensitive real-
time-based method.
The above reported data indicate that the frequency of 
BRAF mutations in indeterminate cases was low also using 
a very sensitive method, depending on the expertise of the 
cytopathologist, on the accuracy to classify the TIR3 class, 
and on a selection bias due to the geographic region where 
the evaluation of the patients was conducted.
An attentive expression profiling analysis was performed 
to identify new potential diagnostic markers.
Thirty/68 cases of indeterminate nodules were submitted 
to surgery upon a clinical evaluation, and in 16/30 a 
histological diagnosis of benign lesions was done, and in 
14 of malignant lesions. The malignancy rate in these 30 
indeterminate FNA patients was high probably because 
the first group of patients undergoing surgery showed 
suspicious aspects with neck ultrasound (i.e., >8 mm; a 
hypoechogenic, solid appearance; irregular or blurred 
margins; presence of microcalcification).
RT Profiler PCR arrays (100) were used for expression 
profiling analysis in all the 30 patients submitted to surgery. 
This technique permits to evaluate the expression profile of 
a specific panel of genes, and was used to analyze 84 genes 
participating in cell-matrix interactions, cell-cell adhesion, 
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and ECM remodeling. In tumors, between epithelial and 
microenvironment stroma cells, dynamic and reciprocal 
interactions, involving CAMs (i.e., integrin and CD44), 
ECM non-cellular components (i.e., thrombospondin 1 and 
FN1), and soluble cytokines exist. Furthermore, in human 
tumors the composition of CAMs and ECMs is changed 
and affects cell growth, survival, migration, adhesion, and 
other stromal and neoplastic cells features (101-103). 
The following genes were identified: 6 genes upregulated 
in malignant nodules with respect to benign ones 
[“transforming growth factor, β-induced (TGFBI), cadherin 1, 
type 1 (CDH1), collagen, type I, α1 (COL1A1), catenin 
(cadherin-associated protein), α1, 102 kDa (CTNNA1), 
integrin α3 (ITGA3), and fibronectin 1 (FN1)”]; 6 genes 
strongly upregulated in FVPTCs vs. FAs [“integrin β2 
(ITGB2), FN1, connective tissue growth factor (CTGF), 
laminin γ1 (LAMC1), catenin (cadherin-associated protein), 
δ1 (CTNND1), and integrin αV (ITGAV)”]. 
Moreover, 6 deregulated genes, {4 upregulated genes 
[secreted phosphoprotein 1 (SPP1), CTNNA1, TIMP 
metallopeptidase inhibitor 1 (TIMP1), and FN1] and 
2 downregulated genes (ADAMTS1 and SELL)}, were 
reported in BRAF-mutated PTCs vs. wild type tumors.
These data agree with previously reported differences 
between malignant and benign thyroid nodules for 
molecules implicated in cell-cell adhesion, cytoskeletal 
reorganization, and cell matrix interactions, such as many 
collagens, catenin, FN1, or integrin (103-110). 
Conclusions
Several genetic mutations occurring in PTCs and FTCs 
can be detected in FNA of thyroid nodules, and can be 
used to ameliorate cancer diagnosis and management of 
patients with thyroid nodules. The greatest experience has 
been obtained with the diagnostic use of BRAF mutation, 
which is strongly specific for malignancy when detected 
using well-validated techniques. The strongest diagnostic 
result can be obtained testing FNA samples for a panel of 
mutations that typically involves BRAF, RAS, TERT, RET/
PTC, and PAX8/PPARγ. Finding any of these mutations in 
a thyroid nodule provides strong indication for malignancy 
and helps to refine clinical management for a significant 
proportion of patients with indeterminate cytology. 
What we know today about the diagnostic value 
of molecular markers it is reported in the Revised 
Management Guidelines for Patients with Thyroid Nodules 
and Differentiated Thyroid Cancer, recently published 
by the ATA (7). This statements suggest to consider gene 
markers such as RET/PTC, BRAF, PAX8/PPARγ, RAS and 
in the pre-operative setting of patient whose cytology has 
indeterminate result at FNAC.
The use of these and other emerging molecular markers 
is expected to ameliorate significantly the accuracy of cancer 
diagnosis in thyroid nodules. However other prospective 
studies are needed to identify more accurate molecular 
markers. Finally, the knowledge of these molecular 
pathways has permitted the development of new targeted 
therapies for aggressive TC (111,112).
The most controversial area of TC research deals with 
the distinction of FAs from FVPTCs that are strongly 
connected cancers, whose differential diagnosis is arduous. 
Up to now, molecular markers have been used to better 
characterize follicular-derived TC hoping that some of 
these markers will be helpful to define indeterminate FNA 
samples.
Some genes, earlier involved in TC pathogenesis, have 
been identified as able to differentiate FVPTCs from 
FAs. The expression of CTGF protein was significantly 
upregulated in TC tissues with respect to benign thyroid 
tumors (113) and CTGF mRNA expression was significantly 
different in FAs or FVPTCs, confirming that CTGF 
could be implicated in the malignancy of TCs. Moreover, 
in FVPTCs it was shown an overexpression of ITGAV 
and ITGB1, belonging to the integrin superfamily, as 
earlier reported in malignant TC (114,115). It was also 
shown that ECM protein FN1 mRNA expression was 
significantly increased in FVPTCs vs. FAs. In
 
1988 
FN1 was demonstrated to be overexpressed in TCs by 
immunohistochemistry for the first time (116), and in 
2004 galectin 3 and oncofetal fibronectin were indicated as 
potential markers for the preoperative diagnosis of TCs (117).
 
Moreover, it was reported that FN1 expression was more 
strongly linked to malignancy with respect to adenomas and 
nonmalignant tissues (106). 
Now a similar expression rate by semiquantitative, RT-
PCR and immunohistochemistry is reported, even if the 
only statistically significant molecule was ITGB2. It has 
to be noted that recently FNA has been used to evaluate 
the chemosensitivity of primary TC cells in humans. This 
might ameliorate the response to treatment, as in vitro drug 
screening with human primary TC cells has a 60% positive 
predictive and a 90% negative predictive value of clinical 
response in vivo in the same patient. This could permit not 
to administer inactive drugs to patients (118,119).
In conclusion, BRAF mutation analysis alone does 
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not permit to ameliorate the diagnostic accuracy. In 
indeterminate TIR3 FNA patients, the combination of 
precise molecular marker expression analysis with molecular 
mutations evaluations could be assessed. For these reasons, 
a further expression analysis of specific molecular markers is 
necessary to draw decisive conclusions. 
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